Your browser doesn't support javascript.
loading
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease.
Weintraub, Daniel; Simuni, Tanya; Caspell-Garcia, Chelsea; Coffey, Christopher; Lasch, Shirley; Siderowf, Andrew; Aarsland, Dag; Barone, Paolo; Burn, David; Chahine, Lama M; Eberling, Jamie; Espay, Alberto J; Foster, Eric D; Leverenz, James B; Litvan, Irene; Richard, Irene; Troyer, Matthew D; Hawkins, Keith A.
  • Weintraub D; Departments of Psychiatry and Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA; Philadelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
  • Simuni T; Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.
  • Caspell-Garcia C; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
  • Coffey C; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
  • Lasch S; Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging, LLC (MNI), New Haven, Connecticut, USA.
  • Siderowf A; Avid Radiopharmaceuticals, Philadelphia, Pennsylvania, USA.
  • Aarsland D; Department of Neurobiology, Care Sciences and Society and the Alzheimer Disease Research Centre, Karolinska Institutet, Stockholm, Sweden; Centre for Age-Related Medicine, Stavanger University Hospital, Stavanger, Norway.
  • Barone P; Neurodegenerative Diseases Centre, Neuroscience Section, Department of Medicine, University of Salerno, Italy.
  • Burn D; Institute for Ageing and Health, Newcastle University, Newcastle, England.
  • Chahine LM; Department of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Eberling J; Michael J. Fox Foundation for Parkinson's Research, New York, New York, USA.
  • Espay AJ; Department of Neurology, University of Cincinnati Academic Health Center, Cincinnati, Ohio, USA.
  • Foster ED; Department of Biostatistics, College of Public Health, University of Iowa, Iowa City, Iowa, USA.
  • Leverenz JB; Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.
  • Litvan I; UCSD Movement Disorder Center, Department of Neurosciences, University of California San Diego, San Diego, California, USA.
  • Richard I; Departments of Neurology and Psychiatry, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA.
  • Troyer MD; Medivation, Inc., San Francisco, California, USA.
  • Hawkins KA; Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.
Mov Disord ; 30(7): 919-27, 2015 Jun.
Article en En | MEDLINE | ID: mdl-25737166
ABSTRACT
UNLABELLED This study was undertaken to determine the prevalence and correlates of cognitive impairment (CI) and neuropsychiatric symptoms (NPS) in early, untreated patients with Parkinson's disease (PD).

BACKGROUND:

Both CI and NPS are common in PD and impact disease course and quality of life. However, limited knowledge is available about cognitive abilities and NPS.

METHODS:

Parkinson's Progression Markers Initiative (PPMI) is a multi-site study of early, untreated PD patients and healthy controls (HCs), the latter with normal cognition. At baseline, participants were assessed with a neuropsychological battery and for symptoms of depression, anxiety, impulse control disorders (ICDs), psychosis, and apathy.

RESULTS:

Baseline data of 423 PD patients and 196 HCs yielded no between-group differences in demographic characteristics. Twenty-two percent of PD patients met the PD-recommended screening cutoff for CI on the Montral Cognitive Assessment (MoCA), but only 9% met detailed neuropsychological testing criteria for mild cognitive impairment (MCI)-level impairment. The PD patients were more depressed than HCs (P < 0.001), with twice as many (14% vs. 7%) meeting criteria for clinically significant depressive symptoms. The PD patients also experienced more anxiety (P < 0.001) and apathy (P < 0.001) than HCs. Psychosis was uncommon in PD (3%), and no between-group difference was seen in ICD symptoms (P = 0.51).

CONCLUSIONS:

Approximately 10% of PD patients in the early, untreated disease state met traditional criteria of CI, which is a lower frequency compared with previous studies. Multiple dopaminergic-dependent NPS are also more common in these patients compared with the general population, but others associated with dopamine replacement therapy are not or are rare. Future analyses of this cohort will examine biological predictors and the course of CI and NPS. © 2015 International Parkinson and Movement Disorder Society.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Índice de Severidad de la Enfermedad / Trastornos del Conocimiento / Trastornos Mentales Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Año: 2015 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Índice de Severidad de la Enfermedad / Trastornos del Conocimiento / Trastornos Mentales Tipo de estudio: Clinical_trials / Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Límite: Aged80 Idioma: En Año: 2015 Tipo del documento: Article